Ampio Pharmaceuticals, Inc. (AMPE)

NYSE MKT - NYSE MKT Delayed Price. Currency in USD
0.83-0.00 (-0.41%)
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.83
Bid0.81 x 1800
Ask0.98 x 500
Day's Range0.82 - 0.85
52wk Range0.77 - 4.32
1y Target EstN/A
Market Cap43M
P/E Ratio (ttm)-1.36
Avg Vol (3m)904,981
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Ampio Reports Additional Peer-Reviewed Publication on Ampion™

    ENGLEWOOD, Colo., Aug. 30, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today publication in the peer-reviewed journal Biochemistry and Biophysics Reports that further describes the modes of action (MOA) of Ampion™ in the treatment of Osteoarthritis. Dr. David Bar-Or, Ampio's Chief Science Officer, noted, "This manuscript reports that in the presence of either IL-1β or TNFα, LMWF-5A (Ampion™) increased the expression of both COX2 mRNA and protein, and this increase was significant compared to that observed with IL-1β- or TNFα-stimulated, saline-treated cells.

  • PR Newswire2 days ago

    Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

    ENGLEWOOD, Colo., Aug. 29, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with an institutional investor providing for the registered sale of 5,000,000 shares of common stock and accompanying warrants to purchase up to 5,000,000 shares of common stock with an exercise price of $1.00 per share, at a combined purchase price of $0.75 per share and accompanying warrant. The Company intends to use the net proceeds from this offering for general corporate purposes as well as advancing the BLA for Ampion™ and its future clinical trials. Financial West Group is acting as the exclusive placement agent for the offering.

  • PR Newswire28 days ago

    Ampio Updates Regulatory Status of AMPION™

    ENGLEWOOD, Colo., Aug. 3, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today that it has filed a meeting request and Briefing Document with the FDA to seek guidance on the filing of the company's Biological License Application (BLA) for Ampion™ to treat patients suffering from pain caused by severe Osteoarthritis (OA) of the knee. In the second quarter of this year, Ampio submitted their Chemistry Manufacturing and Controls (CMC) documents for Ampion™ with the FDA, and requested the Agency provide any related guidance. Ampio also announced that the STRUT Study that treated pain due to OA of the knee with multiple injections of Ampion™, authored by Dr. John Schwappach, the trials Principal Investigator, was accepted for publication in the peer-reviewed journal "Orthopedics."  As soon as the journal is in print, we will post the article on Ampio's website.